Piper Sandler analyst Matthew O’Brien reiterated a Buy rating on Glaukos (GKOS – Research Report) today and set a price target of $105.00. The company’s shares closed yesterday at $92.79.
According to TipRanks, O’Brien is a 4-star analyst with an average return of 6.7% and a 52.36% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Sight Sciences, Atricure, and Medtronic.
Currently, the analyst consensus on Glaukos is a Strong Buy with an average price target of $100.30, an 8.09% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $110.00 price target.
See the top stocks recommended by analysts >>
Based on Glaukos’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $78.05 million and a GAAP net loss of $30.44 million. In comparison, last year the company earned a revenue of $67.68 million and had a net profit of $5.4 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos (GKOS) Company Description:
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
Read More on GKOS:
- Glaukos Quarterly Summary: Performance Insights and Disclosures
- GKOS Earnings this Week: How Will it Perform?
- Glaukos backs FY24 revenue view $350M-$360M, consensus $352.71M
- Glaukos raises FY23 revenue view to $313M from $307M-$310M, consensus $309.02M
- Glaukos reports preliminary Q4 revenue $81M, consensus $76.66M
